Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications

Archives of Neurology

Volumn 64, Issue 11, 2007, Pages 1575-1579

  Volkow, Nora D ^a,b   Fowler, Joanna S ^c   Wang, Gene Jack ^c   Swanson, James M ^d   Telang, Frank ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BACLOFEN; BUPRENORPHINE; DISULFIRAM; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; METHADONE; METHYLPHENIDATE; MODAFINIL; NALTREXONE; NICOTINE GUM; NICOTINE PATCH; RACLOPRIDE C 11; SELEGILINE; TOPIRAMATE; VARENICLINE; VESICULAR TRANSPORT PROTEIN;

ALCOHOLISM; CIGARETTE SMOKING; CINGULATE GYRUS; COCAINE DEPENDENCE; CONDITIONING; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEROIN DEPENDENCE; HUMAN; LEARNING; MOTIVATION; MOTOR PERFORMANCE; NEUROIMAGING; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; NUCLEUS ACCUMBENS; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; REWARD; TOBACCO DEPENDENCE;

BRAIN; DIAGNOSTIC IMAGING; DOPAMINE; HUMANS; RECEPTORS, DOPAMINE D2; SUBSTANCE-RELATED DISORDERS;

EID: 36148955383     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.11.1575     Document Type: Review

References (32)

1. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002; 36(2):229-240.
2. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557-569.
3. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.
4. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effects of dose and infusion duration. J Exp Anal Behav. 1973;20(1): 119-129.
5. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry. 1995;52(6):456-463.
6. Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 2000; 95:S119-S128.
7. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsivity in detoxified cocaine abusers. Nature. 1997;386(6627):830- 833.
8. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum [published online ahead of print July 14, 2005]. Biol Psychiatry. 2005;58(10):779-786. doi:10.10612/j.biopsych.2005.04.044.
9. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36(2):241-263.
10. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex. 2000;10(3):318-325.
11. Vanderschuren LJ, Everitt BJ. Behavioral and neural mechanisms of compulsive drug seeking [November 28, 2005]. Eur J Pharmacol. 2005;526(1-3): 77-88. doi:10.1016/j.ejphar.2005.09.037.
12. Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction [published correction appears in J Neurosci. 2006;26(27):table of contents]. J Neurosci. 2006;26(24):6583-6588.
13. Wong DF, Kuwabara H, Schretlen DJ, et al. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving [published online ahead of print September 13, 2006; published correction appears in Neuropsychopharmacology. 2007;32(1):256]. Neuropsychopharmacology. 2006; 31(12):2716-2727.doi:10.1038/sj.npp.1301194.
14. Thanos PK, Volkow ND, Freimuth P, et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem. 2001;78(5):1094-1103.
15. Volkow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry. 2006;63(9):999-1008.
16. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci. 2004;25(1):42-48.
17. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
18. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3):277-288.
19. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005;108(1):76-85.
20. Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry. 2001;62(suppl 20):11-17.
21. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218.
22. King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8(5):671-682.
23. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction [published online ahead of print February 17, 2006]. Trends Neurosci. 2006;29(4):225-232. doi:10.1016/j.tins.2006.01.008.
24. Whitworth AB, Oberbauer H, Fleischhacker WW, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996; 347(9013):1438-1442.
25. Anton RF, O'Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study; a randomized controlled trial. JAMA. 2006;295 (17):2003-2017.
26. Mardikian PN, Larowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study [published online ahead of print November 16, 2006]. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):389-394. doi:10.1016/j.pnpbp.2006.10.001.
27. Johnson BA, Ait-Daoud N, Bowden Cl, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet. 2003;361(9370): 1677-1685.
28. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55(2):122-125.
29. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-240.
30. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64(12):1440-1448.
31. Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci. 2003;1003:328-345.
32. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53(2):136-143.